New York, NY -- (SBWIRE) -- 11/02/2013 -- StockMarketIntel.com issues a special report on the following stocks: VIVUS, Inc. (NASDAQ:VVUS), First Solar, Inc. (NASDAQ:FSLR), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), NewLead Holdings Ltd (NASDAQ:NEWL)
VIVUS, Inc. (NASDAQ:VVUS) gained 1.28% recently, while trading on 367,044 shares at the price of $9.51. If we look at its trading history of the past 52 weeks, the share price suffered a low of $9.11 and was moved to its maximum level of $15.62.The stock changed hands in a range of $9.28 to $9.53, bringing its market capitalization at about $959.11 million. VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate.
Will VVUS Continue To Move Higher? Find Out Here
First Solar, Inc. (NASDAQ:FSLR) added 17.54% recently, in the current trading session, at $59.10 with a total volume of 15.42 million shares. The stock, on average, trades on a volume of 5.64 million shares. In the past 52 weeks, the share price has not declined below $22.20 and above $59.36.It floated in a range of $54.77 to $59.36 during the recent trading session, with a beta value of 1.70.Its market capitalization now moved to about $5.77 billion. First Solar, Inc. manufactures and sells photovoltaic (PV) solar modules with an advanced thin-film semiconductor technology, and it designs, constructs, and sells PV solar power systems. The Company is a thin-film PV solar module manufacturer and a PV solar module manufacturer. It operates its business in two segments: components segment and systems segment. Its components segment involves the design, manufacture, and sale of solar modules, which convert sunlight into electricity.
Why Should Investors Buy FSLR After The Recent Gain? Just Go Here and Find Out
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) recently recorded a fall of -4.32% and was moving within a range of $1.55-$1.65. Its current trading price is $1.55. The share price hit its 52-week low of $0.37 and $3.65 was the best price. The stock completed the day with a total volume of 651,756 shares, versus an average volume of 2.67 million shares. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115.
Is it the Right to Grab CPRX after the Recent Slump? Get Free Trend Analysis Here
NewLead Holdings Ltd (NASDAQ:NEWL) declined -4.92% in its current trading activity, bringing its market capitalization around $30.71 million. The total number of shares that changed hands during the current session up till now was 211,740 shares, as compared to average trading volume of 1.10 million shares. The share price after opening at $1.23 made a high of $1.25 and hovered above $1.16, while its recent trading price was $1.16. NewLead Holdings Ltd. (NewLead) is an international shipping company engaged in the transportation of refined products, such as gasoline and jet fuel, and dry bulk goods, such as iron ore, coal and grain. NewLead operates in two segments: wet operations, which consists of tankers transporting several different refined petroleum products simultaneously in segregated, coated cargo tanks, and dry operations, which consists of transportation and handling of bulk cargoes through ownership, operation and trading of vessels.
Will NEWL Reach the Bottom after Yesterday’s Correction? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)